EBITDA společnosti Inhibrx
Jaká je hodnota metriky EBITDA společnosti Inhibrx?
Hodnota metriky EBITDA společnosti Inhibrx, Inc. je -$111.79
Jaká je definice metriky EBITDA?
EBITDA je zisk před odečtením úroků, daní, odpisů a amortizací udávající operační výkonnost společnosti.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Inhibrx
Čemu se věnuje společnost Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou ebitda podobnou společnosti Inhibrx
- Hodnota metriky EBITDA společnosti Geron je -$113.06
- Hodnota metriky EBITDA společnosti Pliant Therapeutics je -$112.61
- Hodnota metriky EBITDA společnosti Avalara Inc je -$112.60
- Hodnota metriky EBITDA společnosti Christine International je -¥112.46
- Hodnota metriky EBITDA společnosti Albireo Pharma Inc je -$112.20
- Hodnota metriky EBITDA společnosti Kadmon je -$112.01
- Hodnota metriky EBITDA společnosti Inhibrx je -$111.79
- Hodnota metriky EBITDA společnosti Apollo Future Mobility je -HKD$111.73
- Hodnota metriky EBITDA společnosti Ballard Power Systems je -$111.66
- Hodnota metriky EBITDA společnosti Housing Development and Infrastructure je -₨111.53
- Hodnota metriky EBITDA společnosti ALX Oncology je -$111.40
- Hodnota metriky EBITDA společnosti Provention Bio je -$111.35
- Hodnota metriky EBITDA společnosti Litian Pictures je -¥110.92